EP1226274A2 - Identification of cells for transplantation - Google Patents
Identification of cells for transplantationInfo
- Publication number
- EP1226274A2 EP1226274A2 EP00971573A EP00971573A EP1226274A2 EP 1226274 A2 EP1226274 A2 EP 1226274A2 EP 00971573 A EP00971573 A EP 00971573A EP 00971573 A EP00971573 A EP 00971573A EP 1226274 A2 EP1226274 A2 EP 1226274A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cell
- transplantation
- gene
- expression profile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002054 transplantation Methods 0.000 title claims abstract description 28
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 210000003061 neural cell Anatomy 0.000 claims description 13
- 210000004556 brain Anatomy 0.000 claims description 10
- 210000005172 vertebrate brain Anatomy 0.000 claims description 7
- 101150081664 PAX6 gene Proteins 0.000 claims description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 230000001537 neural effect Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000013782 familial hemiplegic migraine 3 Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 101150038671 strat gene Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
- C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
- C12Q2539/113—Differential Display Analysis [DDA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- This invention relates to the identification of cells suitable for transplantation into a vertebrate brain. More particularly, this invention relates to the identification of multipotent neural cells which are able to repair neural damage following transplantation into the brain.
- the cell transplanted into a damaged brain will be a neural stem cell, e.g. a pluripotent neuroepithelial stem cell which is capable of differentiating into a cell with a neural cell phenotype.
- a neural stem cell e.g. a pluripotent neuroepithelial stem cell which is capable of differentiating into a cell with a neural cell phenotype.
- Sinden etal., Neuroscience (1997) 81 :599-608, discloses that conditionally-immortalised hippocampus neuroepithelial stem cells can be used to improve spatial learning after transplantation into the ischaemia- lesioned hippocampus. See also WO-A-97/10329.
- MHP36 cells (Sinden et al., supra) do aid repair
- MHP15 an apparently similar cell line, MHP15, fails to repair.
- both MHP cell lines were generated from the same tissue source (namely hippocampus), and both are multipotent neural precursor cell lines, i.e. both cell lines have the capacity to generate a full complement of brain cell types, including neurons, astrocytes and oligodendrocytes. Therefore, it would be beneficial if it were possible to identify at an early stage, the cells that were suitable for transplantation, or to have the ability to modify cell lines in order to achieve successful transplantation and repair.
- the present invention is based on the realisation that cells that are suitable for transplantation and repair may be identified on the basis of their gene expression profile.
- the present invention employs, for example, a technique termed differential display (DD) to investigate the differences between repairing and non-repairing cell lines.
- DD differential display
- Differential display is used to visualise the differences in gene expression between two or more cell lines, and it has been found that
- a method for selecting a cell suitable for transplantation into a damaged vertebrate brain comprises:
- Step (i) isolating cells that are, or are capable of differentiating into, a cell with a neural cell phenotype; (ii) obtaining the gene expression profile of the cells; 15 (iii) comparing the expression profile of the cells with that from a control cell known to be suitable for transplantation; and (iv) selecting those cells with a similar expression profile to that of the control.
- the control cell is from the MHP 36 20 cell line. Step (ii) may be carried out by differential display.
- the present invention is not only useful for identifying suitable cells for transplantation, but may be used to identify genes or gene products that may be involved in determining whether or not a neural cell can repair, or not.
- a method for 25 identifying a gene involved in determining whether or not a neural cell can aid repair on transplantation into a damaged brain comprises:
- a method for selecting a cell suitable for transplantation into a damaged brain comprises determining the presence of any of the gene sequences identified herein as SEQ ID NOS. 1 to 5.
- Description of the Invention l o The present invention provides a convenient method for identifying cells that may not be used in transplantation and repair in a damaged vertebrate brain. Using differential display techniques, a cell line can be screened against a control, and a suitable cell line selected for further development.
- a differential displaytechnique is preferred.
- the technique relies on isolating mRNA from a population of cells, and using this to determine the levels of expression of particular genes. This is most often achieved by using reverse transcription to obtain the copy DNA (cDNA), which is co- amplified using specific and semi-quantitative primer sequences. The results 20 are then compared to a control to evaluate differences in gene expression. Kits for carrying out differential display are available commercially.
- the cells used in the method should be capable of differentiating into a cell with a neural cell phenotype, i.e. the differentiated cell should adopt either a neuron, astrocyte or oligodendrocyte phenotype.
- the cells in the 25 undifferentiated state are multi-potent, i.e. they have the capacity to develop into at least two of the neural cell phenotypes above.
- Multi-potent cells are known, and procedures for obtaining such cells will be apparent to the skilled person.
- the differential display technique may be carried out on the cells in the
- the cells are maintained in the undifferentiated state during the technique.
- Conditions to maintain the cells in the undifferentiated state are known in the art, and include culture methods making use of growth factors, and recombinant DNA techniques to insert, for example, oncogenes or conditionally-inducible oncogenes into the cells.
- the present invention provides a convenient way to identify cells that 5 may be used in transplantation and repair in a damaged vertebrate brain. Using the method of the invention, cell lines can be screened against a control, and a suitable cell line selected for further development.
- Genes that are differentially expressed in non-repairing cell lines may be identified. Modification of the genes by, for example, site-directed mutagenesis, o may by carried out to inactivate the genes to provide further cell lines that may be suitable for transplantation. For example, disruption of the Pax6 or 3R2C genes may be carried out to prepare cells for transplantation. Methods for modifying or inactivating the genes will be apparent to the skilled person.
- Modified cell lines, or cell lines identified by the method of the invention 5 as suitable for transplantation may be used in conventional transplantation methods.
- Sinden etal shows the preparation of stem cells for transplantation into the mouse brain.
- the present invention encompasses the use of cells according to the invention, in the manufacture of a composition for the treatment of damage to o the vertebrate brain.
- Suitable formulations for delivery of the cells to the brain will be apparent to the skilled person having regard to the nature of the cell for therapeutic use.
- Appropriate amounts of cells for therapeutic use, in addition to suitable excipients, diluents or carriers, will be apparent to the skilled person based on conventional formulation methods. 5
- the following Example shows a differential display experiment to identify the gene expression profile of the cell lines MHP 36, MHP 15, MHP 3 and SVE 10.
- the cell lines were grown at 33°C, in standard MHP medium containing bFGF, in 175 cm 3 flasks. Cells were allowed to become 90% confluent before being transferred to 39°C, and cultured for a further seven days in the absence of interferon.
- HBSS Gibco BRL
- Trizol Life Technologies
- RNA was precipitated by placing the tubes at -20° C for 1 hour.
- RNA was pelleted by centrifugation at 4,000 rpm for 20 minutes. The pellet was washed in 70% ethanol (made up in DEPC 5 treated water), centrifuged as described above and allowed to air dry at room temperature for ten minutes. The pellet was then resuspended in 439 ⁇ l of DEPC-water and transferred to an RNase free Eppendorf tube.
- RNA sample was resuspended RNA solution; MgCI 2 to a final concentration of 0 5 mM; DDT to 10OmM; RNase inhibitor, 500 units, and DNase I, 700 units.
- the tubes were then incubated at 37 °C for one hour and the RNA purified by the addition of an equal volume of acid phenol/chloroform/isoamyl alcohol (125:24: 1 ) with vortexing for one minute and centrifugation at 14,000 rpm (4°C) for 6 minutes.
- the upper aqueous phase was transferred to a fresh Eppendorf 5 tube and the phenol/chloroform extraction repeated until the interface became clear.
- 8 M LiCI was added to the final aqueous layer to a final concentration of 2.5 M and the tubes placed overnight at -20°C.
- RNA was pelleted by centrifugation at 14,0000 rpm (4°C) for 15 minutes; the pellet was washed with 1 ml of 70% ethanol (DEPC) and allowed 0 to air dry for five minutes. The RNA was then resuspended in 100 ⁇ l of DEPC water. The concentration and purity of RNA was determined by measuring the absorbance at 260 nm and 280 nm. The RNA was then diluted to give aliquots at a concentration of 200 ng/ ⁇ l which were stored at -70°C. Differential Display Analysis
- a 20 ⁇ l reaction using one of the 12 Hieroglyph oligo (dT) anchored 3' primers and 400 ng of total RNA was used to generate enough cDNA for duplicated differential display PCR (DD-PCR) with the same oligo (dT) primer in pairwise combination with all four Hieroglyph arbitrary 5' primers.
- DD-PCR duplicated differential display PCR
- DD-PCR reactions were performed using the Hieroglyph system (Genomyx), Clontech Taq polymerase mix, and [ ⁇ - 33 P]dATP (3,000 Ci/mmole, Amersham). 5
- a PCR core mix containing the appropriate reverse transcriptase (RT) mix and matching anchored primers (AP) prepared in a volume sufficient for the number of reactions needed.
- the core mix included all the DD-PCR components with the exception of the arbitrary primers to be used, which were aliquoted separately into the appropriate tubes. o
- Each individual DD-PCR tube contained the components shown in Table
- the gel was dried on the glass plate in the Genomyx-LR sequencer according to the manufacturer's protocols.
- An autoradiograph of the gel was produced by placing a piece of BioMax MR (Kodak) ultra-high resolution film in contact with the gel, for 16 hours.
- the autoradiograph showed bands corresponding to genes expressed in the non-repairing cells SVE 10 and MHP 15, but not expressed in the repairing cell lines MHP 36 and MHP 3. There were also bands corresponding to genes expressed in the repairing cell lines but not in the non-repairing cell lines.
- the autoradiograph was washed in 90% ethanol and allowed to dry. The autoradiograph was aligned on top of the gel with the aid of autorad markers (Stratgene). The autoradiograph was secured along one long edge with tape. Differentially expressed transcripts (DET) were identified and the bands excised according to the Genomyx protocol. The excised bands were placed into 100 ⁇ l of elution buffer (EB, 10 mM Tris: HCI, pH 7.5) and the DNA allowed to elute at room temperature for six hours. The eluted DNA was stored at -20°C.
- elution buffer EB, 10 mM Tris: HCI, pH 7.5
- SSCP Single Strand Conformation Polymorphism
- PCR products were then purified using PCR purification kit (Qiagen), according to the manufacture's protocols.
- the purified products were eluted in 60 ⁇ l of elution buffer.
- Purified PCR products were sequenced using the Thermosequenase radiolabelled terminator cycle sequencing kit (Amersham). The reactions were performed using the M13 reverse primer (-48) (Genomyx) according to manufacturer's protocols. Sequencing products were loaded on to a 6% Long Ranger (FMC), 8 M Urea, 1xGTB (glycerol-tolerant buffer) gel and electrophoresed for four hours at 2,500 V, 100 W, 50°C in 1xGTB. Following autoradiography, the sequencing ladders were read manually and the resulting sequence data was used to search the GenBank databases (both published and EST).
- FMC Long Ranger
- 1xGTB glycerol-tolerant buffer
- Table 3 shows the gene expression profile of the cell lines used in the experiment.
- MHP 36 and MHP 3 are cells that are suitable for transplantation into a damaged brain. It is clear that the expression profile in MHP36 and MHP3 is similar. Likewise, the profile in MHP15 and SVE10 is similar. However the profiles of MHP36/3 and MHP15/SVE10 are markedly different. This illustrates the difference in function of the two sets of cells as MHP15 and SVE10 cells do not have the ability to repair. Table 3
- neural cells that express the Pax6 gene are not expected to be able to repair brain damage, while neural cell lines that do not express this gene are able to aid repair.
- Pax6 is believed to be a positional specification gene, playing a role in determining the position an embryonic cell is fated to adopt in the developing brain (Fernandez et al, Development (1998) 125: 2099-2111 ).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Pluripotent cells that are suitable for transplantation therapy, to repair neural damage, are identified, e.g. by differential display, from a gene expression profile for a selected cell, which can be compared with that obtained from a control cell.
Description
IDENTIFICATION OF CELLS FOR TRANSPLANTATION
Field of the Invention
This invention relates to the identification of cells suitable for transplantation into a vertebrate brain. More particularly, this invention relates to the identification of multipotent neural cells which are able to repair neural damage following transplantation into the brain. Background to the Invention
There is an increasing awareness that damage to a vertebrate brain can be repaired using cell transplantation technology. Typically, the cell transplanted into a damaged brain will be a neural stem cell, e.g. a pluripotent neuroepithelial stem cell which is capable of differentiating into a cell with a neural cell phenotype.
For example, Sinden etal., Neuroscience (1997) 81 :599-608, discloses that conditionally-immortalised hippocampus neuroepithelial stem cells can be used to improve spatial learning after transplantation into the ischaemia- lesioned hippocampus. See also WO-A-97/10329.
However, it has been found that not all neural stem cells can be transplanted for successful repair of neural damage.
For example, while MHP36 cells (Sinden et al., supra) do aid repair, an apparently similar cell line, MHP15, fails to repair. This difference emerges despite the fact that both MHP cell lines were generated from the same tissue source (namely hippocampus), and both are multipotent neural precursor cell lines, i.e. both cell lines have the capacity to generate a full complement of brain cell types, including neurons, astrocytes and oligodendrocytes. Therefore, it would be beneficial if it were possible to identify at an early stage, the cells that were suitable for transplantation, or to have the ability to modify cell lines in order to achieve successful transplantation and repair. Summary of the Invention
The present invention is based on the realisation that cells that are suitable for transplantation and repair may be identified on the basis of their gene expression profile.
The present invention employs, for example, a technique termed differential display (DD) to investigate the differences between repairing and non-repairing cell lines. Differential display is used to visualise the differences in gene expression between two or more cell lines, and it has been found that
5 cell lines that repair have very similar profiles of gene expression, but very different profiles from those cells that do not repair. This represents a major, unexpected discovery because, apart from their capacity to repair, the cell lines are usually remarkably similar, in morphology, growth characteristics and growth factor responsivity. l o According to one aspect of the present invention, a method for selecting a cell suitable for transplantation into a damaged vertebrate brain comprises:
(i) isolating cells that are, or are capable of differentiating into, a cell with a neural cell phenotype; (ii) obtaining the gene expression profile of the cells; 15 (iii) comparing the expression profile of the cells with that from a control cell known to be suitable for transplantation; and (iv) selecting those cells with a similar expression profile to that of the control. In one embodiment of the invention, the control cell is from the MHP 36 20 cell line. Step (ii) may be carried out by differential display.
The present invention is not only useful for identifying suitable cells for transplantation, but may be used to identify genes or gene products that may be involved in determining whether or not a neural cell can repair, or not.
According to a further aspect of the present invention, a method for 25 identifying a gene involved in determining whether or not a neural cell can aid repair on transplantation into a damaged brain, comprises:
(i) isolating cells that are, or are capable of differentiating into, a cell with a neural cell phenotype; (ii) obtaining the gene expression profile of the cells; 30 (iii) comparing the expression profile of the cells with that from a control cell line known to be suitable for transplantation; and
(iv) isolating those genes that are the same (or different) from those expressed by the control. Using this method, it has been possible to identify a number of genes that are expressed by repairing cell lines but not non-repairing cell lines (and 5 vice versa).
According to a third aspect, a method for selecting a cell suitable for transplantation into a damaged brain, comprises determining the presence of any of the gene sequences identified herein as SEQ ID NOS. 1 to 5. Description of the Invention l o The present invention provides a convenient method for identifying cells that may not be used in transplantation and repair in a damaged vertebrate brain. Using differential display techniques, a cell line can be screened against a control, and a suitable cell line selected for further development.
Although other techniques are known for obtaining gene expression 15 profiles, a differential displaytechnique is preferred. In summary, the technique relies on isolating mRNA from a population of cells, and using this to determine the levels of expression of particular genes. This is most often achieved by using reverse transcription to obtain the copy DNA (cDNA), which is co- amplified using specific and semi-quantitative primer sequences. The results 20 are then compared to a control to evaluate differences in gene expression. Kits for carrying out differential display are available commercially. The cells used in the method should be capable of differentiating into a cell with a neural cell phenotype, i.e. the differentiated cell should adopt either a neuron, astrocyte or oligodendrocyte phenotype. Preferably, the cells in the 25 undifferentiated state are multi-potent, i.e. they have the capacity to develop into at least two of the neural cell phenotypes above. Multi-potent cells are known, and procedures for obtaining such cells will be apparent to the skilled person.
The differential display technique may be carried out on the cells in the
30 differentiated or undifferentiated state. It is however preferred if the cells are maintained in the undifferentiated state during the technique. Conditions to maintain the cells in the undifferentiated state are known in the art, and include
culture methods making use of growth factors, and recombinant DNA techniques to insert, for example, oncogenes or conditionally-inducible oncogenes into the cells.
The present invention provides a convenient way to identify cells that 5 may be used in transplantation and repair in a damaged vertebrate brain. Using the method of the invention, cell lines can be screened against a control, and a suitable cell line selected for further development.
Genes that are differentially expressed in non-repairing cell lines may be identified. Modification of the genes by, for example, site-directed mutagenesis, o may by carried out to inactivate the genes to provide further cell lines that may be suitable for transplantation. For example, disruption of the Pax6 or 3R2C genes may be carried out to prepare cells for transplantation. Methods for modifying or inactivating the genes will be apparent to the skilled person.
Modified cell lines, or cell lines identified by the method of the invention 5 as suitable for transplantation, may be used in conventional transplantation methods. For example, Sinden etal, supra, shows the preparation of stem cells for transplantation into the mouse brain.
The present invention encompasses the use of cells according to the invention, in the manufacture of a composition for the treatment of damage to o the vertebrate brain. Suitable formulations for delivery of the cells to the brain will be apparent to the skilled person having regard to the nature of the cell for therapeutic use. Appropriate amounts of cells for therapeutic use, in addition to suitable excipients, diluents or carriers, will be apparent to the skilled person based on conventional formulation methods. 5 The following Example shows a differential display experiment to identify the gene expression profile of the cell lines MHP 36, MHP 15, MHP 3 and SVE 10.
Example
The cell lines were grown at 33°C, in standard MHP medium containing bFGF, in 175 cm3 flasks. Cells were allowed to become 90% confluent before being transferred to 39°C, and cultured for a further seven days in the absence of interferon.
The cells were washed for five minutes with 20 ml of HBSS (Gibco BRL). The cells were lysed by adding 20 ml of Trizol (Life Technologies), and incubating at 37 °C for ten minutes. The lysate was then transferred to a 50 ml Falcon tube (Stardts) and 5 ml of chloroform added. The tubes were mixed o vigorously for one minute and the phases separated by centrifugation at 4,000 rpm for 15 minutes. The upper aqueous phase was transferred to a fresh 50 ml tube and 7 ml of isopropanol added. RNA was precipitated by placing the tubes at -20° C for 1 hour. The RNA was pelleted by centrifugation at 4,000 rpm for 20 minutes. The pellet was washed in 70% ethanol (made up in DEPC 5 treated water), centrifuged as described above and allowed to air dry at room temperature for ten minutes. The pellet was then resuspended in 439 μl of DEPC-water and transferred to an RNase free Eppendorf tube.
To remove any contaminating DNA from the RNA sample, the following was added to the resuspended RNA solution; MgCI2 to a final concentration of 0 5 mM; DDT to 10OmM; RNase inhibitor, 500 units, and DNase I, 700 units. The tubes were then incubated at 37 °C for one hour and the RNA purified by the addition of an equal volume of acid phenol/chloroform/isoamyl alcohol (125:24: 1 ) with vortexing for one minute and centrifugation at 14,000 rpm (4°C) for 6 minutes. The upper aqueous phase was transferred to a fresh Eppendorf 5 tube and the phenol/chloroform extraction repeated until the interface became clear. 8 M LiCI was added to the final aqueous layer to a final concentration of 2.5 M and the tubes placed overnight at -20°C.
The RNA was pelleted by centrifugation at 14,0000 rpm (4°C) for 15 minutes; the pellet was washed with 1 ml of 70% ethanol (DEPC) and allowed 0 to air dry for five minutes. The RNA was then resuspended in 100 μl of DEPC water. The concentration and purity of RNA was determined by measuring the
absorbance at 260 nm and 280 nm. The RNA was then diluted to give aliquots at a concentration of 200 ng/μl which were stored at -70°C. Differential Display Analysis
All 3' anchoring and 5' arbitrary primers were obtained from the Genomyx Hieroglyph mRNA profile kit. The differential display procedure can be divided into three steps: cDNA synthesis, PCR amplification and gel electrophoresis. First strand cDNA synthesis was carried using the Qiagen Omniscript reverse transcriptase.
A 20 μl reaction using one of the 12 Hieroglyph oligo (dT) anchored 3' primers and 400 ng of total RNA was used to generate enough cDNA for duplicated differential display PCR (DD-PCR) with the same oligo (dT) primer in pairwise combination with all four Hieroglyph arbitrary 5' primers.
2 μl of the 200 ng/μl RNA solution was added to a 0.2 ml thin-walled PCR tube along with 2 μl of Hieroglyph T7 (dT12) anchored primer (AP) (2 μM). This was then heated at 70 °C for five minutes before being placed on ice. To the denatured RNA/primer solution the following was added: lOxOmniscript reverse transcriptase (RT) buffer, 2 μl; 5 mM dNTP's, 2 μl; 0.1M DTT; 0.5 μl RNASEOUT RNase inhibitor (40μ/μl)(Gibco BRL); 1 μl Omniscript (1 unit/μl) and DEPC-water to 20μl. The reaction mixtures were then incubated at 42°C 0 for 1 hour.
Differential Display PCR for each sample was then carried out in duplicate. DD-PCR reactions were performed using the Hieroglyph system (Genomyx), Clontech Taq polymerase mix, and [α-33P]dATP (3,000 Ci/mmole, Amersham). 5 For each cDNA sub-population, a PCR core mix containing the appropriate reverse transcriptase (RT) mix and matching anchored primers (AP) prepared in a volume sufficient for the number of reactions needed. The core mix included all the DD-PCR components with the exception of the arbitrary primers to be used, which were aliquoted separately into the appropriate tubes. o Each individual DD-PCR tube contained the components shown in Table
1.
Table 1
Following DD-PCR, radiolabelled cDNA fragments were electrophoretically separated on a polyacrylamide gel under denaturing conditions. This involved using the Genomyx LR sequencer and LR-optimized HR-1000 polyacrylamide gel formulations. 4.5% and 6% HR-1000 gels were prepared according to manufacturers instructions; 4.5% gels were used to resolve fragments in the size range of 700 bp to 2 kb, while 6% gels were used to separate fragments in the size range of 100 bp to 600 bp.
7 μl of each DD-PCR sample was mixed with 4 μl of sample loading dye (Genomyx) and heated at 95 °C for 3 minutes before being chilled on ice. 3 μl of this heat-denatured sample was then added to a gel lane. Duplicate reactions were loaded in adjacent lanes and samples generated with the same primer pairs in consecutive lanes. 6% gels were used for 6 hours at 2,500 V, 100 W, at 50°C; and 4.5% gels were used for 16 hours at 1 ,500 V, 100 W, at 50°C.
Following electrophoresis, the gel was dried on the glass plate in the Genomyx-LR sequencer according to the manufacturer's protocols. An autoradiograph of the gel was produced by placing a piece of BioMax MR (Kodak) ultra-high resolution film in contact with the gel, for 16 hours.
The autoradiograph showed bands corresponding to genes expressed in the non-repairing cells SVE 10 and MHP 15, but not expressed in the repairing cell lines MHP 36 and MHP 3. There were also bands corresponding to genes expressed in the repairing cell lines but not in the non-repairing cell lines.
Before excising bands from the gel, the autoradiograph was washed in 90% ethanol and allowed to dry. The autoradiograph was aligned on top of the gel with the aid of autorad markers (Stratgene). The autoradiograph was secured along one long edge with tape. Differentially expressed transcripts (DET) were identified and the bands excised according to the Genomyx protocol. The excised bands were placed into 100 μl of elution buffer (EB, 10 mM Tris: HCI, pH 7.5) and the DNA allowed to elute at room temperature for six hours. The eluted DNA was stored at -20°C.
Single Strand Conformation Polymorphism (SSCP) gel analysis was used to eliminate false positives that may arise due to the co-migration of fragments of identical size but different sequences. This procedure involved a limited reamplification of the isolated fragments (SSCP-PCR) followed by the separation of the products of this amplification on a SSCP gel. PCR conditions were similar to those used for DD-PCR, with the exception that the number of cycles were reduced to 2 at the low annealing temperature (50°C), and to 10 cycles at the high annealing temperature (60°C). 4 μl of the SSCP-PCR reaction was added to 10 μl of SSCP-loading buffer (80% formamide, 0.01% bromophenol blue, 0.01 % xylene cyanol, 1 mM EDTA, 10 mM NaOH) and denatured at 95°C for 10 minutes before being loaded onto an agarose gel. Samples were electrophoresed for 16 hours at 8 W in 0.6x tris borate EDTA buffer (TBE) on the Genomyx-LR sequencer. Following autoradiography, areas of the gel corresponding to candidate differentially expressed transcripts were excised and placed into 100 μl of elution buffer (EB). Sequencing and Identification ofDETs The recovered differentially expressed cDNA was reamplified by PCR to provide significant template material to allow for direct sequencing. The PCR reactions contained the components shown in Table 2.
Table 2
The PCR products were then purified using PCR purification kit (Qiagen), according to the manufacture's protocols. The purified products were eluted in 60 μl of elution buffer. Purified PCR products were sequenced using the Thermosequenase radiolabelled terminator cycle sequencing kit (Amersham). The reactions were performed using the M13 reverse primer (-48) (Genomyx) according to manufacturer's protocols. Sequencing products were loaded on to a 6% Long Ranger (FMC), 8 M Urea, 1xGTB (glycerol-tolerant buffer) gel and electrophoresed for four hours at 2,500 V, 100 W, 50°C in 1xGTB. Following autoradiography, the sequencing ladders were read manually and the resulting sequence data was used to search the GenBank databases (both published and EST).
Table 3 shows the gene expression profile of the cell lines used in the experiment. MHP 36 and MHP 3 are cells that are suitable for transplantation into a damaged brain. It is clear that the expression profile in MHP36 and MHP3 is similar. Likewise, the profile in MHP15 and SVE10 is similar. However the profiles of MHP36/3 and MHP15/SVE10 are markedly different. This illustrates the difference in function of the two sets of cells as MHP15 and SVE10 cells do not have the ability to repair.
Table 3
Analysis of the expression products revealed that the non-repairing MHP15 cells expressed a gene termed Pax6 (Gotz et al, Neuron (1998), 21 ; 1031 -1044), while cells from MHP36 did not express this gene.
Therefore, neural cells that express the Pax6 gene are not expected to be able to repair brain damage, while neural cell lines that do not express this gene are able to aid repair.
Pax6 is believed to be a positional specification gene, playing a role in determining the position an embryonic cell is fated to adopt in the developing brain (Fernandez et al, Development (1998) 125: 2099-2111 ).
Further analysis revealed that the non-repairing, non-multipotential cells expressed the gene 3R2C (GeneBank Accession No. D25216). The MHP 36 cells did not express this gene when cultured under permissive conditions.
Claims
1. A method for selecting a cell suitable for transplantation into a damaged vertebrate brain, comprising:
(i) selecting cells that are, or are capable of differentiating into, a cell with a neural cell phenotype;
(ii) obtaining the gene expression profile of the cells;
(iii) comparing the expression profile of the cells with that from a control cell known to be suitable for transplantation; and (iv) selecting those cells with similar gene expression profiles to that of the control.
2. A method for identifying a gene, the expression of which can determine whether or not a neural cell can repair a damaged brain, comprising:
(i) selecting cells that are, or are capable of differentiating into, a cell with a neural cell phenotype; (ii) obtaining the gene expression profile of the cells;
(iii) comparing the expression profile of the cells with that from a control cell known to be suitable for transplantation; and (iv) isolating those genes that are the same (or different) from those expressed by the control. 3. A method according to claim 1 or claim 2, wherein the control cell does not express the gene Pax6 or 3R2C.
5. A method according to any preceding claim, wherein step (ii) is carried out by differential display.
4. A method according to any preceding claim, wherein the control cell is MHP36.
6. A method for selecting a call suitable for transplantation into a damaged brain, which comprises determining the presence of any of the gene sequences identified herein as SEQ ID NOS. 1 to 5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9925210 | 1999-10-25 | ||
GBGB9925210.8A GB9925210D0 (en) | 1999-10-25 | 1999-10-25 | Identification of cells for transplantation |
PCT/GB2000/004103 WO2001031058A2 (en) | 1999-10-25 | 2000-10-24 | Identification of cells for transplantation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1226274A2 true EP1226274A2 (en) | 2002-07-31 |
Family
ID=10863327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00971573A Withdrawn EP1226274A2 (en) | 1999-10-25 | 2000-10-24 | Identification of cells for transplantation |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1226274A2 (en) |
JP (1) | JP2003512082A (en) |
KR (1) | KR20020065492A (en) |
CN (1) | CN1420936A (en) |
AU (1) | AU1041201A (en) |
CA (1) | CA2386438A1 (en) |
GB (1) | GB9925210D0 (en) |
IL (1) | IL149057A0 (en) |
WO (1) | WO2001031058A2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071697A (en) * | 1992-08-03 | 2000-06-06 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Method for testing the differentiation status in pancreatic cells of a mammal |
US6187534B1 (en) * | 1997-09-24 | 2001-02-13 | Cornell Research Foundation, Inc. | Methods of evaluating transplant rejection |
WO1999027076A1 (en) * | 1997-11-25 | 1999-06-03 | Arc Genomic Research | Pluripotent embryonic stem cells and methods of obtaining them |
CA2323074A1 (en) * | 1998-03-13 | 1999-09-16 | Baylor College Of Medicine | Compositions and methods for the treatment and prevention of metastatic disorders |
-
1999
- 1999-10-25 GB GBGB9925210.8A patent/GB9925210D0/en not_active Ceased
-
2000
- 2000-10-24 CN CN00814824A patent/CN1420936A/en active Pending
- 2000-10-24 AU AU10412/01A patent/AU1041201A/en not_active Abandoned
- 2000-10-24 WO PCT/GB2000/004103 patent/WO2001031058A2/en not_active Application Discontinuation
- 2000-10-24 IL IL14905700A patent/IL149057A0/en unknown
- 2000-10-24 CA CA002386438A patent/CA2386438A1/en not_active Abandoned
- 2000-10-24 JP JP2001533193A patent/JP2003512082A/en active Pending
- 2000-10-24 EP EP00971573A patent/EP1226274A2/en not_active Withdrawn
- 2000-10-24 KR KR1020027005257A patent/KR20020065492A/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0131058A2 * |
Also Published As
Publication number | Publication date |
---|---|
KR20020065492A (en) | 2002-08-13 |
AU1041201A (en) | 2001-05-08 |
IL149057A0 (en) | 2002-11-10 |
WO2001031058A3 (en) | 2002-05-30 |
GB9925210D0 (en) | 1999-12-22 |
CA2386438A1 (en) | 2001-05-03 |
WO2001031058A2 (en) | 2001-05-03 |
JP2003512082A (en) | 2003-04-02 |
CN1420936A (en) | 2003-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liang et al. | Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction | |
Condit et al. | Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus | |
US8003375B2 (en) | Qualitative differential screening | |
Biswal et al. | Complementary nuclear RNA's of murine sarcoma-leukemia virus complex in transformed cells | |
AU2839999A (en) | Qualitative differential screening | |
Scolnick et al. | Characterizatiion of rat genetic sequences of Kirsten sarcoma virus: distinct class of endogenous rat type C viral sequences | |
US6432640B1 (en) | P53-induced apoptosis | |
US20110015085A1 (en) | Repetitive Sequence-Free DNA Libraries | |
JP2003533966A (en) | Gene transcription pattern identification method | |
JP2003533966A5 (en) | ||
EP0648222A1 (en) | Methods of single nucleotide primer extension to detect specific alleles and kits therefor | |
US20060228714A1 (en) | Nucleic acid representations utilizing type IIB restriction endonuclease cleavage products | |
US6465215B1 (en) | Identification of cells for transplantation | |
Bossard et al. | In VivoFootprinting with Limiting Amounts of Embryo Tissues: A Role for C/EBPβ in Early Hepatic Development | |
EP1226274A2 (en) | Identification of cells for transplantation | |
US6265165B1 (en) | Methods for EST-specific full length cDNA cloning | |
WO2004048555A1 (en) | Restoration of methylation states in cells | |
Marazita | Genetic etiologies of facial clefting | |
Kayser et al. | Patient-derived stem cell line UKMi005-A (hiPSC) harboring a non-synonymous heterozygous KCNJ5 gene variant | |
Frederick et al. | Regulation of anti-late RNA synthesis in bacteriophage T4: A delayed early control | |
Maher et al. | The HPRT gene as a model system for mutation analysis | |
Suzuki et al. | Identification of differentially expressed mRNAs during neuronal differentiation of P19 embryonal carcinoma cells | |
US20040241734A1 (en) | Methods for in situ hybridization without the need for competitior DNA | |
Zuo et al. | mRNA differential display of colonic mucosa cells in ulcerative colitis | |
Xue et al. | A novel mouse gene, HemT, encoding an hematopoietic cell-specific transcript |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020426 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20050506 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051117 |